具体数据详见《鲁商健康产业发展股份有限公司 2022 年年度报告》。 特此公告。 鲁商健康产业发展股份有限公司董事会 2023 年 3 月 31 日 证券代码：600223 证券简称：鲁商发展 编号：临 2023-011 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2022 年 10-12 月，公司房地产项目实现签约金额 11.26 亿元，同比减少 61.20%；1-12 月实现签约金额 67.38 亿元，同比减少 53.99%。2022 年 10-12 月 实现签约面积 10.38 万平方米，同比减少 63.17%；1-12 月实现签约金额面积 63.50 万平方米，同比减少 53.68%。2022 年 10-12 月无新开工；1-12 月新开工 面积 48.89 万平方米，同比减少 64.51%。2022 年 10-12 月竣工面积 12.12 万平 方米，同比减少 73.43%；1-12 月竣工面积 124.56 万平方米，同比增加 8.57%。 上述签约及新开工数据较上年同期减少主要是由于房地产市场下行及公司 ...

（2022 年 4 月） 投资者关系活动 □特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他电话会议 参与单位名称及 | --- | --- | |----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 华泰证券 国泰君安 中信证券 国信证券 华安证券 东吴证券 | | 人员姓名 | 国金证券 浙商证券 德邦商社 广发证券 开源证券 兴证证券 财通 人寿养老 中信建投证券 上海证券 工银 银华 朱雀 融 通 交银施罗德 华夏基金 中银基金 海富通 泰达宏利 弘毅远 | | | 方 太平养老 中信建投基金 金鹰基金 前海联合基金 安信基 金等 | | --- | --- | ...

（2022 年 5 月） □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 √其他电话会议 国金证券、国君资管、国投瑞银、华泰证券、华夏久盈、 参与单位名称及 凯石基金、前海联合基金、泰达宏利基金、同犇投资、溪牛投 人员姓名 资、朱雀基金、易鑫安、域秀资产、浙商基金、中信建投、赛 富亚洲等。 时间 2022 年 05 月 09 日 16：00-17：00 地点 线上 上市公司接待人 董秘：李璐，证代：代玮玉，IR：张泰生，福瑞达：张红阳、 员姓名 张泽、张学涛、魏杰。 证券代码：600223 证券简称：鲁商发展 鲁商健康产业发展股份有限公司投资者关系活动记录表 | --- | --- | |----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------| | ...

（2022 年 6 月） 证券代码：600223 证券简称：鲁商发展 鲁商健康产业发展股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|---------|--------------------------------------------------------|--------------------|------------------------------------------------------------------|-----------------| | 投资者关系活动 \n类别 | | □特定对象调研 \n新闻发布会 \n√其他电话会议 | □ \n□ \n□ 路演活动 | 分析师会议 \n业绩说明会 | | | | | 安信资管 | 财通证券 | 东方证券 东吴证券 | 光大证券 | | 参与单位名称及 | | 国金证券 | 国泰君安 | 国信证券 国元证券 | 华泰证券 | | 人员姓名 | | 平安证券 | 上海证券 | 申万宏源 西部证券 | 兴业证券 | | | ...

证券代码：600223 证券简称：鲁商发展 编号：临 2022-039 | --- | --- | --- | --- | --- | |-------|------------------------------|--------------------------|-------|------------------------------------------------------------------| | | 鲁商健康产业发展股份有限公司 | | | | | | 关于参加山东辖区上市公司 | | 2022 | 年度投资者 | | | | 网上集体接待日活动的公告 | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 | | | | | | | 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为加强与投资者之间的沟通交流，提高上市公司透明度和治理水平，鲁商健 康产业发展股份有限公司（以下简称"公司"）将参加由山东证监局、山东上市 公司协会联合举办的"山东辖区上市公司 2022 年度投资者网上集体接待日"活 动，现将有关事项公告如 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥3,693,939,070.78, representing a year-on-year increase of 61.89%[7] - The net profit attributable to shareholders for Q3 2022 was -¥35,428,385.95, a decrease of 118.45% compared to the same period last year[7] - The net cash flow from operating activities for Q3 2022 was ¥339,801,052.18, down 75.02% year-on-year[7] - The basic earnings per share for Q3 2022 was -¥0.04, a decline of 121.05% compared to the same period last year[11] - For the first nine months of 2022, the company achieved operating revenue of RMB 8.529 billion and a net profit attributable to the parent company of RMB 154 million[23] - The company's total revenue for the first three quarters of 2022 reached ¥8.53 billion, representing a significant increase of 34.4% compared to ¥6.35 billion in the same period of 2021[39] - The company's operating profit for the first three quarters of 2022 was approximately ¥391.55 million, a decrease of 42.1% compared to ¥674.86 million in the same period of 2021[42] - Total profit for the first three quarters of 2022 was approximately ¥355.23 million, down 44.7% from ¥642.40 million in 2021[42] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was approximately ¥153.77 million, a decline of 69.5% compared to ¥503.15 million in 2021[42] - Basic earnings per share for the first three quarters of 2022 were ¥0.15, down 70% from ¥0.50 in the same period of 2021[44] - The company reported a total comprehensive income of approximately ¥185.85 million for the first three quarters of 2022, down 62.6% from ¥496.57 million in 2021[42] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥59,610,838,521.61, a decrease of 2.94% from the end of the previous year[11] - As of September 30, 2022, total assets amounted to RMB 59.611 billion, with net assets attributable to the parent company at RMB 4.038 billion[23] - The company's long-term borrowings decreased to ¥3.20 billion from ¥3.75 billion, a reduction of approximately 14.7%[35] - The total liabilities as of September 30, 2022, were ¥53.68 billion, down from ¥54.92 billion at the end of 2021, indicating a decrease of about 2.3%[35] - The company's cash and cash equivalents decreased to ¥688.77 million from ¥730.25 million, a decline of approximately 5.7%[32] - The company reported a decrease in accounts payable to ¥7.17 billion from ¥7.47 billion, a reduction of about 4.0%[35] - The company’s deferred income tax assets increased to ¥111.55 million from ¥101.25 million, reflecting a growth of approximately 10.1%[32] - The total equity attributable to shareholders decreased to ¥4.04 billion from ¥4.73 billion, a decline of approximately 14.6%[35] Revenue Segmentation - The increase in operating revenue for Q3 2022 was mainly due to increased health real estate settlements and cosmetic sales[14] - In the health real estate sector, the company recorded a signed amount of RMB 5.612 billion and a signed area of 531,300 square meters during the first nine months of 2022[23] - The cosmetics segment generated revenue of RMB 1.429 billion with a gross margin of 58.56% in the same period[24] - The pharmaceutical segment reported revenue of RMB 337 million with a gross margin of 52.32% for the first nine months of 2022[24] - The raw materials and derivatives segment achieved revenue of RMB 232 million with a gross margin of 32.47%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,127[15] - The company’s major shareholder, Shandong Commercial Group, holds 524,739,200 shares, with a total of 93 million shares pledged[20] Strategic Initiatives - The company is actively transforming from real estate to the health industry, focusing on reducing inventory and ensuring delivery[23] - The company launched a skin microbiome scientific skincare platform and collaborated with a well-known IP for a co-branded product[24] - The company is in the process of transferring a 31.5% stake in Yangzhou Lusu Health Industry Development Co., Ltd., which will no longer be included in the consolidated financial statements after the transfer[26] Cash Flow Analysis - Cash flow from operating activities for the first three quarters of 2022 was approximately ¥1.23 billion, a decrease of 74.5% compared to ¥4.80 billion in 2021[46] - Cash inflow from investment activities for the first three quarters of 2022 was approximately ¥144.95 million, a slight increase from ¥137.32 million in 2021[48] - Cash outflow from financing activities for the first three quarters of 2022 was approximately ¥11.28 billion, an increase from ¥10.12 billion in 2021[48] - The net cash flow from financing activities for the first three quarters of 2022 was approximately -¥1.53 billion, an improvement from -¥5.46 billion in 2021[48] - The company's cash and cash equivalents at the end of the first three quarters of 2022 were approximately ¥1.85 billion, an increase from ¥1.71 billion at the end of 2021[48]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 4.84 billion, an increase of 18.88% compared to RMB 4.07 billion in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 39.18% to approximately RMB 189.20 million from RMB 311.10 million in the previous year[21]. - The basic earnings per share for the first half of 2022 was RMB 0.19, down 38.71% from RMB 0.31 in the same period last year[23]. - The total assets at the end of the reporting period were approximately RMB 61.73 billion, a slight increase of 0.51% from RMB 61.42 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 2.26% to approximately RMB 4.62 billion from RMB 4.73 billion at the end of the previous year[21]. - The weighted average return on net assets for the first half of 2022 was 4.00%, a decrease of 3.34 percentage points from 7.34% in the same period last year[26]. - The company achieved a revenue of 4.835 billion CNY in the first half of 2022, representing a year-on-year growth of 18.88%[54]. - The net profit attributable to the parent company was 189 million CNY, a decrease of 39.18% year-on-year[54]. - The company’s total assets reached 61.731 billion CNY, with a net asset attributable to the parent company of 4.620 billion CNY, reflecting a growth of 0.51% and a decline of 2.26% respectively compared to the beginning of the period[54]. Operational Challenges - The net cash flow from operating activities decreased by 74.20%, primarily due to reduced sales collections in the health real estate sector influenced by market conditions[27]. - The company faced increased financial expenses due to interest capitalization from temporarily halted health real estate projects[26]. - The overall gross margin decreased year-on-year due to the impact of the pandemic and market downturn[26]. - The health real estate segment recorded a contract sales amount of 3.98 billion CNY, with a sales area of 372,000 square meters, down 56.05% and 55.02% year-on-year due to the downturn in the real estate industry[54]. - The company experienced a decline in sales collection compared to the previous year, posing challenges to its financing and operational capabilities[106]. Strategic Initiatives - The company plans to strengthen product promotion, which has led to an increase in sales expenses[26]. - The company is transitioning from a developer to a lifestyle service provider, focusing on health real estate and wellness services, with operations in multiple cities including Jinan and Qingdao[34]. - The company aims to expand its biopharmaceutical segment by increasing investment in traditional Chinese medicine innovation and developing a MAH platform[66]. - The company plans to enhance its health real estate segment by focusing on cash flow stability and project sales acceleration[65]. - The company is exploring new strategies in public infrastructure and affordable rental housing to accelerate its asset-light transformation[65]. Market Trends - The biopharmaceutical sector is experiencing a shift towards health-centered approaches, with new opportunities arising from policies supporting traditional Chinese medicine[38]. - The market for hyaluronic acid is expected to grow significantly due to rising consumer demand and policy support, indicating a broad development space ahead[39]. - The demand for biological food additives is increasing as consumers become more aware of food safety, leading to a trend of replacing chemical preservatives[41]. Product Development - The company has launched a series of hyaluronic acid-based food products, expanding its product matrix significantly since 2021[46]. - The company has developed a strong brand matrix in the biopharmaceutical sector, with notable brands such as "施沛特" and "明仁" recognized in the orthopedic field[48]. - The company has established 3 national-level and 13 provincial-level R&D platforms, with 243 authorized patents and significant achievements in hyaluronic acid research[47]. - The company launched 108 new cosmetic products and obtained 45 new authorized patents, bringing the total to 243 patents[62]. - The company’s new product ratio increased to 10% while maintaining growth in existing popular products[58]. Environmental Responsibility - The company’s subsidiaries are listed as key pollutant discharge units, indicating a focus on environmental responsibility[123]. - The company invested approximately CNY 2.963 million in environmental protection measures during the first half of 2022[136]. - The company has established a wastewater treatment station that meets discharge standards, utilizing aerobic and anaerobic treatment processes[137]. - The company has committed to continuous improvement in environmental protection capabilities among its personnel[136]. - The company has developed emergency response plans for potential environmental pollution incidents, which have been reviewed by internal and external experts[141]. Corporate Governance - The company reported a 59.29% shareholder attendance at the 2021 annual general meeting, with 598,366,887 shares represented[112]. - The company appointed new executives, including a new chairman and CFO, to support its strategic transformation[113][117]. - The company did not propose any profit distribution or capital reserve increase for the half-year period[120]. - The company has no significant litigation or arbitration matters during the reporting period[163]. - The company has not faced any non-compliance issues or penalties involving its directors, supervisors, or senior management[163].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600223 证券简称：鲁商发展 鲁商健康产业发展股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |----------------------------------------------|------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 1,482,210,648 ...

Financial Performance - The company achieved a net profit attributable to shareholders of 361,900,881.01 RMB for the year 2021, with the parent company reporting a net profit of 351,504,529.99 RMB[6]. - The company's operating revenue for 2021 was approximately ¥12.36 billion, a decrease of 9.20% compared to 2020[27]. - Net profit attributable to shareholders for 2021 was approximately ¥361.90 million, down 43.34% year-on-year[30]. - The total profit for 2021 was 644 million RMB, down 24.58% compared to the previous year[80]. - Net profit attributable to the parent company was 362 million RMB, reflecting a significant decline of 43.34% year-on-year[80]. - The total assets at the end of 2021 were approximately ¥61.42 billion, a slight decrease of 0.14% from the previous year[27]. - The weighted average return on equity for 2021 was 8.34%, a decrease of 11.69 percentage points from 2020[30]. - The basic earnings per share for 2021 was ¥0.36, a decrease of 43.75% compared to 2020[30]. Dividend and Profit Distribution - The proposed cash dividend distribution is 1.1 RMB per 10 shares, totaling 111,006,741.89 RMB, with 303,331,957.80 RMB available for distribution to shareholders[6]. - The company has a remaining undistributed profit of 192,325,215.91 RMB to be carried forward to future years[6]. - The company is committed to sustainable development and shareholder returns as part of its profit distribution strategy[6]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to future strategies and financial conditions[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[8]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The audit report issued by Da Xin Accounting Firm is a standard unqualified opinion[5]. Business Operations and Revenue Streams - The company achieved a contract sales amount of ¥14.645 billion in 2021, a decrease of 16.78% year-on-year, with a sales area of 1.3711 million square meters, down 18.19%[39]. - The company completed new construction of 1.3775 million square meters in 2021, a decrease of 26.78% compared to the previous year[39]. - The company expanded its property management operations, managing approximately 22.87 million square meters by the end of 2021[39]. - The company actively developed light asset businesses, including health care and commercial management, and secured multiple government and market construction projects[39]. Cosmetics and Pharmaceutical Segments - In 2021, the cosmetics business achieved revenue of 1.495 billion yuan, a year-on-year increase of 117.01%[40]. - The medical segment reported revenue of 541 million yuan, reflecting a year-on-year growth of 8.71%[43]. - The raw materials and additives segment generated revenue of 241 million yuan, with a year-on-year increase of 21.96%[43]. - The total revenue for the pharmaceutical group reached 2.181 billion yuan, accounting for 17.64% of the company's total revenue, an increase of 8.03 percentage points from the previous year[43]. - The net profit attributable to the parent company was 180 million yuan, representing 49.68% of the total net profit, a year-on-year growth of 33.05%[43]. Research and Development - The company established three new research centers in collaboration with universities, enhancing its R&D capabilities[49]. - The company has been awarded 197 patents and has undertaken over 30 major national and provincial scientific projects, showcasing its strong R&D strength[75]. - The company has initiated six R&D projects in health real estate, enhancing product quality and competitiveness[113]. - The company completed nearly 300 safety and efficacy evaluations for its raw materials in compliance with new regulations[171]. Market Trends and Strategic Initiatives - The health industry operation sector benefits from China's economic growth, urbanization, and rising consumer income, creating strong demand for property services[53]. - The cosmetics market in China reached a size of CNY 367.8 billion in the first 11 months of 2021, with a growth rate of 15.3%[55]. - The introduction of strong regulatory measures in the cosmetics sector is expected to benefit legitimate companies, enhancing market competitiveness[55]. - The company aims to transform from a real estate developer to a lifestyle service provider, focusing on creating better living experiences[61]. Sales and Marketing - The company's online cosmetic sales increased significantly, with revenue of CNY 1,396,293,394.30, reflecting a 144.84% year-over-year growth[1]. - The brand Yilian achieved sales of over 15 million bottles of its hyaluronic acid moisturizing spray in 2021, ranking first in the category on Tmall and winning the Tmall Golden Makeup Award[159]. - The brand Aier Doctor's four key products accounted for approximately 70% of total sales in 2021, with the new product "Anti-Gravity Water Emulsion" exceeding 10 million in sales within months of launch[161]. - The company plans to continue expanding its direct sales and online presence to enhance revenue growth in the cosmetics segment[93]. Investment and Financing - The company secured strategic investments totaling 738 million yuan, setting a record for state-owned enterprises in Shandong Province[45]. - The total financing amount at the end of the period was RMB 1,939.94 million, with an average financing cost of 9.975%[150]. - The company financed RMB 5.45 billion from non-related parties and RMB 381,400 from related parties during the reporting period, both within the authorized limits set by the shareholders' meeting[150]. Land and Development Projects - The company holds a total of 1,000,000 square meters of land for development across various regions, with a significant portion in Qingdao at 247,793 square meters[139]. - The planned construction area for the projects in Qingdao includes 639,981 square meters, indicating a strong focus on residential and commercial developments[140]. - The company has reported a total of 1,000,000,000 RMB in investments across multiple projects in Qingdao, showcasing its strategic focus on this key market[140].

证券代码：600223 证券简称：鲁商发展 编号：临 2021-059 鲁商健康产业发展股份有限公司 关于参加山东辖区上市公司 2021 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为加强与投资者之间的沟通交流，提高上市公司透明度和治理水平，鲁商健 康产业发展股份有限公司（以下简称"公司"）将参加由山东证监局、山东上市 公司协会联合举办的"山东辖区上市公司 2021 年度投资者网上集体接待日"活 动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可登陆"全景·路演天下"网站（http://rs.p5w.net/) 参与公司此次投资者网上集体接待日活动，时间为 2021 年 11 月 16 日（周二） 14：00-16：00。 届时公司董事会秘书李璐女士、财务总监杨云龙先生、证券事务代表代玮玉 女士将参与本次投资者网上集体接待日活动，与投资者进行在线交流，欢迎广大 投资者积极参与。 特此公告。 鲁商健康产业发展股份有限 ...